Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focal, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Hambrecht & Quist Funds invest $1.4 mil. in the privately held Cambridge, Massachusetts firm, increasing to $20 mil. the amount raised through the private placement of Series D preferred stock ('The Gray Sheet" Aug. 23, p. 16). Frazier Investment Securities and Invemed Associates handled the offering. To date, Focal has raised $30.2 mil. in three rounds of financing. Founded in 1991, the firm plans to begin clinical trials in 1994 of a biodegradable photopolymer gel to prevent post-surgical adhesions and also is developing the Pavent biodegradable "paving stent" for the prevention of restenosis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel